RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ENDPOINTS NEWS Jan 31, 2024How do you explain the share price since the move to the Nasdaq? It was at $6-8 when first listed.
SINCE then, Promis has:
- received approval for an IND from the FDA
- released postitive pre-clinical data
- started Phase 1 trials
Pretty good news, right?
Well, as everyone knows, the share price has gone nowhere but down - almost back to penny-stock status not too long ago - and now is just barely keeping its head above Nasdaq-delisting terrority.
I don't know about anyone else, but that doesn't make a whole lot of sense to me.